$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

$eltp Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-Q Financial Statement

#000149315224006661 Filed on February 14, 2024

Income Statement

Concept	2024 Q1	2023 Q4
Revenue	$17.95M	$15.54M
YoY Change	107.71%	67.99%
Cost Of Revenue	$9.831M	$8.498M
YoY Change	89.05%	96.21%
Gross Profit	$8.118M	$7.041M
YoY Change	135.9%	43.13%
Gross Profit Margin	45.23%	45.31%
Selling, General & Admin	$2.291M	$1.761M
YoY Change	186.58%	46.87%
% of Gross Profit	28.22%	25.01%
Research & Development	$1.718M	$1.404M
YoY Change	-29.17%	-2.74%
% of Gross Profit	21.16%	19.94%
Depreciation & Amortization	$328.4K	$336.6K
YoY Change	-4.57%	6.99%
% of Gross Profit	4.04%	4.78%
Operating Expenses	$4.390M	$3.508M
YoY Change	24.16%	18.52%
Operating Profit	$3.729M	$3.533M
YoY Change	-4062.79%	80.32%
Interest Expense	-$913.1K	$121.6K
YoY Change	94.62%	-62.31%
% of Operating Profit	-24.49%	3.44%
Other Income/Expense, Net	-$822.1K	-$3.627M
YoY Change		-445.35%
Pretax Income	$1.993M	-$94.26K
YoY Change	-332.85%	-103.13%
Income Tax	-$1.332M	-$800.0K
% Of Pretax Income	-66.85%
Net Earnings	$3.326M	$706.4K
YoY Change	-370.56%	-76.22%
Net Earnings / Revenue	18.53%	4.55%
Basic Earnings Per Share		$0.00
Diluted Earnings Per Share	$0.00	$0.00
COMMON SHARES
Basic Shares Outstanding	1.018B shares	1.014B shares
Diluted Shares Outstanding		1.024B shares

Balance Sheet

Concept	2024 Q1	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.106M	$5.816M
YoY Change	-9.27%	-67.52%
Cash & Equivalents	$7.106M	$5.816M
Short-Term Investments
Other Short-Term Assets	$524.2K	$1.006M
YoY Change	-49.25%	-9.24%
Inventory	$12.93M	$14.33M
Prepaid Expenses
Receivables	$19.45M	$16.01M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$40.01M	$37.16M
YoY Change	86.02%	12.04%
LONG-TERM ASSETS
Property, Plant & Equipment	$10.18M	$10.10M
YoY Change	-2.41%	-1.32%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$94.24K	$7.260K
YoY Change	348.33%	-92.09%
Other Assets	$22.59M	$20.66M
YoY Change	774.28%	701.77%
Total Long-Term Assets	$43.64M	$37.54M
YoY Change	125.11%	92.01%
TOTAL ASSETS
Total Short-Term Assets	$40.01M	$37.16M
Total Long-Term Assets	$43.64M	$37.54M
Total Assets	$83.65M	$74.70M
YoY Change	104.55%	41.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.714M	$2.891M
YoY Change	10.93%	96.35%
Accrued Expenses	$5.302M	$11.88M
YoY Change	5.03%	154.15%
Deferred Revenue	$13.33K	$13.33K
YoY Change	0.0%	0.0%
Short-Term Debt	$4.000M	$4.000M
YoY Change
Long-Term Debt Due	$609.0K	$343.9K
YoY Change	95.9%	-27.06%
Total Short-Term Liabilities	$13.05M	$19.16M
YoY Change	66.59%	187.91%
LONG-TERM LIABILITIES
Long-Term Debt	$4.760M	$3.518M
YoY Change	33.65%	-77.29%
Other Long-Term Liabilities	$8.261M	$5.606M
YoY Change
Total Long-Term Liabilities	$13.02M	$9.124M
YoY Change	217.42%	-42.57%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.05M	$19.16M
Total Long-Term Liabilities	$13.02M	$9.124M
Total Liabilities	$26.07M	$28.28M
YoY Change	118.43%	25.47%
SHAREHOLDERS EQUITY
Retained Earnings	-$116.4M	-$119.7M
YoY Change	-14.73%	-11.5%
Common Stock	$1.068M	$1.018M
YoY Change	5.36%	0.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$306.8K	$306.8K
YoY Change	0.0%	0.0%
Treasury Stock Shares
Shareholders Equity	$57.58M	$46.41M
YoY Change
Total Liabilities & Shareholders Equity	$83.65M	$74.70M
YoY Change	104.55%	41.7%

Cashflow Statement

Concept	2024 Q1	2023 Q4
OPERATING ACTIVITIES
Net Income	$3.326M	$706.4K
YoY Change	-370.56%	-76.22%
Depreciation, Depletion And Amortization	$328.4K	$336.6K
YoY Change	-4.57%	6.99%
Cash From Operating Activities	$2.060M	-$2.396M
YoY Change	-30.61%	321.88%
INVESTING ACTIVITIES
Capital Expenditures	$403.6K	$406.0K
YoY Change	-24.72%	57084.51%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$403.6K	-$406.0K
YoY Change	-24.72%	57084.51%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-361.5K	-30.66K
YoY Change	-97.11%	-60.37%
NET CHANGE
Cash From Operating Activities	2.060M	-2.396M
Cash From Investing Activities	-403.6K	-406.0K
Cash From Financing Activities	-361.5K	-30.66K
Net Change In Cash	1.295M	-2.832M
YoY Change	-112.86%	338.49%
FREE CASH FLOW
Cash From Operating Activities	$2.060M	-$2.396M
Capital Expenditures	$403.6K	$406.0K
Free Cash Flow	$1.656M	-$2.802M
YoY Change	-31.91%	392.76%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Entity Central Index Key EntityCentralIndexKey	0001053369
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset		usd
CY2023Q1	us-gaap	Other Loans Payable OtherLoansPayable		usd
CY2023Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent		usd
CY2023Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent		usd
CY2022Q4	ELTP	Change In Fair Value Of Stockbased Liabilities ChangeInFairValueOfStockbasedLiabilities		usd
CY2022Q4	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement		usd
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement		usd
CY2023Q4	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets		usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets		usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts		usd
	ELTP	Change In Fair Value Of Stockbased Liabilities ChangeInFairValueOfStockbasedLiabilities		usd
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement		usd
	ELTP	Noncash Rent Expense And Lease Accretion NoncashRentExpenseAndLeaseAccretion		usd
	ELTP	Increase Decrease In Deferred Income Tax Assets IncreaseDecreaseInDeferredIncomeTaxAssets		usd
	ELTP	Increase Decrease In Finance Lease Liability IncreaseDecreaseInFinanceLeaseLiability		usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
	ELTP	Proceeds From Amortization Of Finance Leases Rightofuse Assets ProceedsFromAmortizationOfFinanceLeasesRightofuseAssets		usd
	ELTP	Recognition Of Right Of Use Asset And Lease Liabilities RecognitionOfRightOfUseAssetAndLeaseLiabilities		usd
CY2023Q4	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther		usd
	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther		usd
CY2022Q4	us-gaap	Dilutive Securities DilutiveSecurities		usd
	us-gaap	Dilutive Securities DilutiveSecurities		usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent		usd
CY2023Q1	ELTP	Accrued Codevelopment Profit Split AccruedCodevelopmentProfitSplit		usd
CY2023Q1	us-gaap	Litigation Reserve Current LitigationReserveCurrent		usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent		usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo		usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree		usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour		usd
CY2023Q4	ELTP	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour		usd
	ELTP	Awarded Shares AwardedShares		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-15697
	dei	Entity Registrant Name EntityRegistrantName	ELITE PHARMACEUTICALS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	22-3542636
	dei	Entity Address Address Line1 EntityAddressAddressLine1	165 LUDLOW AVENUE
	dei	Entity Address City Or Town EntityAddressCityOrTown	NORTHVALE
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07647
	dei	City Area Code CityAreaCode	(201)
	dei	Local Phone Number LocalPhoneNumber	750-2646
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	ELTP
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1017781199	shares
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5816211	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7832247	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	194600	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	16009614	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3094549	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	14325041	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	9550716	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1005636	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1032785	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	37156502	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	21510297	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	15578471	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14586335	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10095029	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10426158	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6341228	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6341228	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	408428	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	26231	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	13062	usd
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	20233603	usd
CY2023Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	2171821	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	427999	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	412434	usd
CY2023Q4	us-gaap	Security Deposit SecurityDeposit	7259	usd
CY2023Q1	us-gaap	Security Deposit SecurityDeposit	21018	usd
CY2023Q4	us-gaap	Other Assets OtherAssets	435258	usd
CY2023Q1	us-gaap	Other Assets OtherAssets	433452	usd
CY2023Q4	us-gaap	Assets Assets	74696279	usd
CY2023Q1	us-gaap	Assets Assets	40896018	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2890717	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2446810	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11884645	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5047726	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	13333	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	13333	usd
CY2023Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	115822	usd
CY2023Q1	us-gaap	Secured Debt Current SecuredDebtCurrent	110822	usd
CY2023Q4	us-gaap	Loans Payable Current LoansPayableCurrent	190607	usd
CY2023Q1	us-gaap	Loans Payable Current LoansPayableCurrent	200032	usd
CY2023Q4	us-gaap	Other Loans Payable OtherLoansPayable	4000000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	37444	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	26231	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	14914	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19158799	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	7833637	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	8889	usd
CY2023Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	18890	usd
CY2023Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	909654	usd
CY2023Q1	us-gaap	Secured Long Term Debt SecuredLongTermDebt	1029018	usd
CY2023Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	2407077	usd
CY2023Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	2532502	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	200939	usd
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	5597200	usd
CY2023Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	521711	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	9123759	usd
CY2023Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4102121	usd
CY2023Q4	us-gaap	Liabilities Liabilities	28282558	usd
CY2023Q1	us-gaap	Liabilities Liabilities	11935758	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1445000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1445000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1017881199	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1014015081	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1017781199	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1013915081	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1017885	usd
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	1014019	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	165417811	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	164750980	usd
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	100000	shares
CY2023Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	100000	shares
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	306841	usd
CY2023Q1	us-gaap	Treasury Stock Value TreasuryStockValue	306841	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-119715134	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-136497898	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	46413721	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	28960260	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	74696279	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	40896018	usd
CY2023Q4	ELTP	Revenue From Manufacturing Fees RevenueFromManufacturingFees	14791110	usd
CY2022Q4	ELTP	Revenue From Manufacturing Fees RevenueFromManufacturingFees	7798159	usd
	ELTP	Revenue From Manufacturing Fees RevenueFromManufacturingFees	36208217	usd
	ELTP	Revenue From Manufacturing Fees RevenueFromManufacturingFees	21312663	usd
CY2023Q4	ELTP	Revenue From Licensing Fees RevenueFromLicensingFees	747690	usd
CY2022Q4	ELTP	Revenue From Licensing Fees RevenueFromLicensingFees	1451907	usd
	ELTP	Revenue From Licensing Fees RevenueFromLicensingFees	2467844	usd
	ELTP	Revenue From Licensing Fees RevenueFromLicensingFees	4200888	usd
CY2023Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15538800	usd
CY2022Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9250066	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	38676061	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	25513551	usd
CY2023Q4	us-gaap	Cost Of Revenue CostOfRevenue	8497727	usd
CY2022Q4	us-gaap	Cost Of Revenue CostOfRevenue	4330841	usd
	us-gaap	Cost Of Revenue CostOfRevenue	20437354	usd
	us-gaap	Cost Of Revenue CostOfRevenue	12360935	usd
CY2023Q4	us-gaap	Gross Profit GrossProfit	7041073	usd
CY2022Q4	us-gaap	Gross Profit GrossProfit	4919225	usd
	us-gaap	Gross Profit GrossProfit	18238707	usd
	us-gaap	Gross Profit GrossProfit	13152616	usd
CY2023Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1403790	usd
CY2022Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1443361	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5165684	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3775107	usd
CY2023Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1711275	usd
CY2022Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1186049	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4906187	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4356752	usd
CY2023Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	49815	usd
CY2022Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13030	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	107592	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	24325	usd
CY2023Q4	us-gaap	Depreciation And Amortization DepreciationAndAmortization	343537	usd
CY2022Q4	us-gaap	Depreciation And Amortization DepreciationAndAmortization	317685	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	999059	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	933531	usd
CY2023Q4	us-gaap	Operating Expenses OperatingExpenses	3508417	usd
CY2022Q4	us-gaap	Operating Expenses OperatingExpenses	2960125	usd
	us-gaap	Operating Expenses OperatingExpenses	11178522	usd
	us-gaap	Operating Expenses OperatingExpenses	9089715	usd
CY2023Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	3532656	usd
CY2022Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	1959100	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	7060185	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	4062901	usd
CY2023Q4	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-2417772	usd
CY2022Q4	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	372894	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-5075489	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	561070	usd
CY2023Q4	ELTP	Change In Fair Value Of Stockbased Liabilities ChangeInFairValueOfStockbasedLiabilities	-2854556	usd
	ELTP	Change In Fair Value Of Stockbased Liabilities ChangeInFairValueOfStockbasedLiabilities	-4921376	usd
CY2023Q4	us-gaap	Interest Expense InterestExpense	121628	usd
CY2022Q4	us-gaap	Interest Expense InterestExpense	322681	usd
	us-gaap	Interest Expense InterestExpense	371478	usd
	us-gaap	Interest Expense InterestExpense	782221	usd
CY2023Q4	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	1761792	usd
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	1761792	usd
CY2022Q4	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	1000000	usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	1000000	usd
CY2023Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	5249	usd
CY2022Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	15	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	16085	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	187	usd
CY2023Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3626915	usd
CY2022Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1050228	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8590466	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	779036	usd
CY2023Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-94259	usd
CY2022Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	3009328	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1530281	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	4841937	usd
CY2023Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-800613	usd
CY2022Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	39250	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-18313045	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	50837	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	706354	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	2970078	usd
	us-gaap	Net Income Loss NetIncomeLoss	16782764	usd
	us-gaap	Net Income Loss NetIncomeLoss	4791100	usd
CY2023Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2023Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2022Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.01
CY2023Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1014768071	shares
CY2022Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1013915081	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1014265162	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1012480115	shares
CY2023Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1024448445	shares
CY2022Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1013915081	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1019511813	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1012480115	shares
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	28960260	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	1141809	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	15000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	30117069	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	14934601	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	42777	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	45094447	usd
CY2023Q4	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	251867	usd
CY2023Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	311238	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	706354	usd
CY2023Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	49815	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	46413721	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	25222027	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	305883	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5322	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	25533232	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	1515139	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5974	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	60000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	77062	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	27191407	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	27191407	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	2970078	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	2970078	usd
CY2022Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13029	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	30174514	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	30174514	usd
	us-gaap	Net Income Loss NetIncomeLoss	16782764	usd
	us-gaap	Net Income Loss NetIncomeLoss	4791100	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	992136	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	933531	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	194600	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	18153	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	61621	usd
	ELTP	Noncash Compensation Accrued NoncashCompensationAccrued	563105	usd
	ELTP	Noncash Compensation Accrued NoncashCompensationAccrued	430778	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-5075489	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	561070	usd
	ELTP	Change In Fair Value Of Stockbased Liabilities ChangeInFairValueOfStockbasedLiabilities	-4921376	usd
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	1761792	usd
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	107592	usd
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	24325	usd
	ELTP	Noncash Rent Expense And Lease Accretion NoncashRentExpenseAndLeaseAccretion	602	usd
	ELTP	Deferred Revenue Expenses DeferredRevenueExpenses	10001	usd
	ELTP	Deferred Revenue Expenses DeferredRevenueExpenses	10003	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	13109665	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2487930	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4774325	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1860688	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-40908	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	581113	usd
	ELTP	Increase Decrease In Deferred Income Tax Assets IncreaseDecreaseInDeferredIncomeTaxAssets	18061782	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3702825	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-309950	usd
	ELTP	Increase Decrease In Finance Lease Liability IncreaseDecreaseInFinanceLeaseLiability	-2915	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-20005	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-61182	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5341537	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	370021	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	406007	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5200407	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-406007	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5200407	usd
	us-gaap	Repayments Of First Mortgage Bond RepaymentsOfFirstMortgageBond	125000	usd
	us-gaap	Repayments Of First Mortgage Bond RepaymentsOfFirstMortgageBond	115000	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	4000000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	14550001	usd
	ELTP	Proceeds From Amortization Of Finance Leases Rightofuse Assets ProceedsFromAmortizationOfFinanceLeasesRightofuseAssets	6923	usd
	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	134850	usd
	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	230770	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3747073	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14204231	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2000471	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	9373845	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8244681	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8940396	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6244210	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	18314241	usd
	us-gaap	Interest Paid Net InterestPaidNet	119412	usd
	us-gaap	Interest Paid Net InterestPaidNet	782221	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	292000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	127522	usd
	ELTP	Stock Issued In Satisfaction Of Accrued Directors Salaries And Consultant Fees StockIssuedInSatisfactionOfAccruedDirectorsSalariesAndConsultantFees	563105	usd
	ELTP	Stock Issued In Satisfaction Of Accrued Directors Salaries And Consultant Fees StockIssuedInSatisfactionOfAccruedDirectorsSalariesAndConsultantFees	137067	usd
	ELTP	Recognition Of Right Of Use Asset And Lease Liabilities RecognitionOfRightOfUseAssetAndLeaseLiabilities	272620	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5816211	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17909077	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	427999	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	405164	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6244210	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18314241	usd
CY2023Q4	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	706354	usd
CY2022Q4	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	3342972	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	16782764	usd
CY2023Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15538800	usd
CY2022Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9250066	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	38676061	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	25513551	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	427999	usd
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	412434	usd
CY2023	ELTP	Finitelived Intangible Assets Impairment FinitelivedIntangibleAssetsImpairment	292807	usd
	ELTP	Finitelived Intangible Assets Impairment FinitelivedIntangibleAssetsImpairment	0	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	6341228	usd
	ELTP	Finitelived Intangible Assets Impairment FinitelivedIntangibleAssetsImpairment	0	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6341228	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	6634035	usd
CY2023	ELTP	Finitelived Intangible Assets Impairment FinitelivedIntangibleAssetsImpairment	292807	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6341228	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	4791100	usd
CY2022Q4	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	372894	usd
	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	561070	usd
	us-gaap	Income Tax Examination Likelihood Of Unfavorable Settlement IncomeTaxExaminationLikelihoodOfUnfavorableSettlement	These tax benefits are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution
CY2023	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	1000000	usd
CY2023Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	706354	usd
CY2022Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	2970078	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	16782764	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	5352170	usd
CY2023Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1014768071	shares
CY2022Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1013915081	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1014265162	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1012480115	shares
CY2023Q4	us-gaap	Dilutive Securities DilutiveSecurities	9680374	usd
	us-gaap	Dilutive Securities DilutiveSecurities	5246651	usd
CY2023Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1024448445	shares
CY2022Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1013915081	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1019511813	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1012480115	shares
CY2023Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2023Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2022Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.01
CY2023Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	521711	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-5075489	usd
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	5597200	usd
CY2022Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	936837	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	561070	usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	375767	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	194600	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	5544848	usd
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2352330	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1247307	usd
CY2023Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	1791311	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	7532886	usd
CY2023Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	5407075	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	14325041	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	9550716	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	25673500	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	25012493	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	15578471	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14586335	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10095029	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10426158	usd
CY2023Q4	us-gaap	Depreciation Depreciation	336614	usd
CY2022Q4	us-gaap	Depreciation Depreciation	314610	usd
	us-gaap	Depreciation Depreciation	992136	usd
	us-gaap	Depreciation Depreciation	923365	usd
CY2023Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	6934812	usd
CY2023Q1	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	4125000	usd
CY2023Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	414989	usd
CY2023Q4	ELTP	Accrued Codevelopment Profit Split AccruedCodevelopmentProfitSplit	3389949	usd
CY2023Q4	ELTP	Accrued Consultant Contract Fees AccruedConsultantContractFees	10000	usd
CY2023Q1	ELTP	Accrued Consultant Contract Fees AccruedConsultantContractFees	193333	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	125000	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	125000	usd
CY2023Q4	ELTP	Accrued Director Dues AccruedDirectorDues	22500	usd
CY2023Q1	ELTP	Accrued Director Dues AccruedDirectorDues	70000	usd
CY2023Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	75000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	712384	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	615000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	119404	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11884645	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5047726	usd
CY2023Q4	us-gaap	Interest Expense Debt InterestExpenseDebt	30384	usd
CY2022Q4	us-gaap	Interest Expense Debt InterestExpenseDebt	317844	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	101478	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	579109	usd
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	22222	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	13333	usd
CY2023Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	8889	usd
CY2023Q1	us-gaap	Deferred Revenue DeferredRevenue	32223	usd
CY2023Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	13333	usd
CY2023Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	18890	usd
	us-gaap	Lessee Finance Lease Description LesseeFinanceLeaseDescription	(i) ownership of the underlying asset transfers to the Company by the end of the lease term; (ii) the lease contains an option to purchase the underlying asset that the Company is reasonably expected to exercise; (iii) the lease term is for a major part of the remaining economic life of the underlying asset; (iv) the present value of the sum of lease payments and any residual value guaranteed by the Company equals or exceeds substantially all of the fair value of the underlying asset; or (v) the underlying asset is of a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term.
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	408428	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	26231	usd
CY2023Q4	ELTP	Lease Assets LeaseAssets	434659	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	37444	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	26231	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	200939	usd
CY2023Q4	ELTP	Lease Liabilities LeaseLiabilities	264614	usd
CY2023Q4	us-gaap	Payments For Rent PaymentsForRent	0	usd
CY2022Q4	us-gaap	Payments For Rent PaymentsForRent	0	usd
	us-gaap	Payments For Rent PaymentsForRent	0	usd
	us-gaap	Payments For Rent PaymentsForRent	58248	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	8087	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	16286	usd
CY2023Q4	ELTP	Lease Liability Payments Remainder Of Fiscal Year LeaseLiabilityPaymentsRemainderOfFiscalYear	24373	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	18870	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	65145	usd
CY2023Q4	ELTP	Lease Liability Payments Due Next Twelve Months LeaseLiabilityPaymentsDueNextTwelveMonths	84015	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	65145	usd
CY2023Q4	ELTP	Lease Liability Payments Due Year Two LeaseLiabilityPaymentsDueYearTwo	65145	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	65145	usd
CY2023Q4	ELTP	Lease Liability Payments Due Year Three LeaseLiabilityPaymentsDueYearThree	65145	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	65145	usd
CY2023Q4	ELTP	Lease Liability Payments Due Year Four LeaseLiabilityPaymentsDueYearFour	65145	usd
CY2023Q4	ELTP	Finance Lease Liability Payments Due After Year Four FinanceLeaseLiabilityPaymentsDueAfterYearFour	43429	usd
CY2023Q4	ELTP	Lease Liability Payments Due After Year Four LeaseLiabilityPaymentsDueAfterYearFour	43429	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	727	usd
CY2023Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	81911	usd
CY2023Q4	ELTP	Lease Liability Undiscounted Excess Amount LeaseLiabilityUndiscountedExcessAmount	82638	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	26230	usd
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	238384	usd
CY2023Q4	ELTP	Lease Liabilities LeaseLiabilities	264614	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y9M18D
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P4Y10M24D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.060	pure
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.125	pure
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.1521
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.1521
CY2023Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P3Y3M18D
CY2023Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P4Y1M6D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.79	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.80	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0427	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0469	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0299	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0401	pure
CY2023Q4	ELTP	Common Stock Issued In Payment Of Directors Salaries CommonStockIssuedInPaymentOfDirectorsSalaries	1642971	shares
CY2023Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	60000	usd
CY2023Q4	us-gaap	Share Price SharePrice	0.1533
CY2023Q4	ELTP	Common Stock Value Issued In Payment Of Directors Salaries CommonStockValueIssuedInPaymentOfDirectorsSalaries	251867	usd
CY2023Q4	ELTP	Common Stock Issued In Payment Of Consulting Fees CommonStockIssuedInPaymentOfConsultingFees	2223147	shares
CY2023Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	153333	usd
CY2023Q4	us-gaap	Share Price SharePrice	0.14
CY2023Q4	ELTP	Common Stock Value Issued In Payment Of Consulting Fees CommonStockValueIssuedInPaymentOfConsultingFees	311238	usd
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1017881199	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1017781199	shares
CY2023Q1	ELTP	Stock Based Compensation StockBasedCompensation	4278333	usd
	ELTP	Increase Decrease In Stock Based Liabilities IncreaseDecreaseInStockBasedLiabilities	4729509	usd
	ELTP	Common Stock Issued CommonStockIssued	-311238	usd
	ELTP	Settlement Of Noncash Liability SettlementOfNoncashLiability	-1761792	usd
CY2023Q4	ELTP	Stock Based Compensation StockBasedCompensation	6934812	usd
CY2023Q4	ELTP	Common Stock Issued In Payment Of Consulting Fees CommonStockIssuedInPaymentOfConsultingFees	2223147	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.80	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.81	pure
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	50000.00	usd
CY2023Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-800000	usd
CY2022Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	40000.00	usd
	ELTP	Discrete Tax Benefit DiscreteTaxBenefit	18100000	usd
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	15370000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.07
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M24D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4100000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.09
	ELTP	Sharebased Compensation Arrangement By Sharebased Payment Award Weighted Average Remaining Contractual Term Granted SharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAverageRemainingContractualTermGranted	P10Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	3840000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0.07
	ELTP	Sharebased Compensation Arrangement By Sharebased Payment Award Weighted Average Remaining Contractual Term Expired And Forfeited SharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAverageRemainingContractualTermExpiredAndForfeited	P1Y9M18D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	15630000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.05
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1429822	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	343334	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.19
	ELTP	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableOutstandingWeightedAverageRemainingContractualTerm	P4Y7M6D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	6850	usd
CY2023Q4	ELTP	Price Difference Between Exercise Price And Quoted Price PriceDifferenceBetweenExercisePriceAndQuotedPrice	0.14
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	450470	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y4M13D
CY2023Q4	ELTP	Common Stock Issued In Payment Of Consulting Fees CommonStockIssuedInPaymentOfConsultingFees	2223147	shares
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-18300000	usd
	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001493152-24-006661-index-headers.html	Edgar Link	pending
0001493152-24-006661-index.html	Edgar Link	pending
0001493152-24-006661.txt	Edgar Link	pending
0001493152-24-006661-xbrl.zip	Edgar Link	pending
eltp-20231231.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
eltp-20231231_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
eltp-20231231_lab.xml	Edgar Link	unprocessable
eltp-20231231_cal.xml	Edgar Link	unprocessable
eltp-20231231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2024 Q1 Form 10-Q Financial Statement

#000149315224006661 Filed on February 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2024 Q1 Form 10-Q Financial Statement

#000149315224006661 Filed on February 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp